Literature DB >> 28475567

A role for oncostatin M in inflammatory bowel disease.

Walter M Kim1, Arthur Kaser2, Richard S Blumberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28475567      PMCID： PMC5527753          DOI： 10.1038/nm.4338

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

1.  Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation.

Authors:  M C Kullberg; A G Rothfuchs; D Jankovic; P Caspar; T A Wynn; P L Gorelick; A W Cheever; A Sher
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Adenoviral transfer of the murine oncostatin M gene suppresses dextran-sodium sulfate-induced colitis.

Authors:  Ana L Sanchez; Carrie M Langdon; Mahmood Akhtar; Jun Lu; Carl D Richards; Premysl Bercik; Derek M McKay
Journal:  J Interferon Cytokine Res       Date:  2003-04       Impact factor: 2.607

3.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

4.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Toshifumi Hibi; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-02       Impact factor: 22.682

5.  Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.

Authors:  Bruce E Sands; William J Sandborn; Gert Van Assche; Milan Lukas; Jing Xu; Alexandra James; Brihad Abhyankar; Karen Lasch
Journal:  Inflamm Bowel Dis       Date:  2017-01       Impact factor: 5.325

6.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Authors:  Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

7.  IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis.

Authors:  Marika C Kullberg; Dragana Jankovic; Carl G Feng; Sophie Hue; Peter L Gorelick; Brent S McKenzie; Daniel J Cua; Fiona Powrie; Allen W Cheever; Kevin J Maloy; Alan Sher
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

8.  Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members.

Authors:  Florian Beigel; Matthias Friedrich; Corina Probst; Karl Sotlar; Burkhard Göke; Julia Diegelmann; Stephan Brand
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

Review 9.  Management of inflammatory bowel disease in poor responders to infliximab.

Authors:  Iván Guerra; Fernando Bermejo
Journal:  Clin Exp Gastroenterol       Date:  2014-09-18

10.  Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Authors:  Nathaniel R West; Ahmed N Hegazy; Benjamin M J Owens; Samuel J Bullers; Bryan Linggi; Sofia Buonocore; Margherita Coccia; Dieter Görtz; Sébastien This; Krista Stockenhuber; Johanna Pott; Matthias Friedrich; Grigory Ryzhakov; Frédéric Baribaud; Carrie Brodmerkel; Constanze Cieluch; Nahid Rahman; Gerhard Müller-Newen; Raymond J Owens; Anja A Kühl; Kevin J Maloy; Scott E Plevy; Satish Keshav; Simon P L Travis; Fiona Powrie
Journal:  Nat Med       Date:  2017-04-03       Impact factor: 53.440
View more
  5 in total

Review 1.  Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut.

Authors:  Mousumi Mahapatro; Lena Erkert; Christoph Becker
Journal:  Cells       Date:  2021-01-09       Impact factor: 6.600

2.  Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's Disease.

Authors:  Xavier Roblin; Adrian Serone; Oh Kyu Yoon; Luting Zhuo; Ethan Grant; Jacky Woo; Jinfeng Liu; René Galien; Geert D'Haens
Journal:  Inflamm Bowel Dis       Date:  2022-08-01       Impact factor: 7.290

3.  Meta-Analysis of Expression Profiling Data Indicates Need for Combinatorial Biomarkers in Pediatric Ulcerative Colitis.

Authors:  Xinxiu Li; Eun Jung Lee; Danuta R Gawel; Sandra Lilja; Samuel Schäfer; Huan Zhang; Mikael Benson
Journal:  J Immunol Res       Date:  2020-01-29       Impact factor: 4.818

4.  Molecular Simulation of Oncostatin M and Receptor (OSM-OSMR) Interaction as a Potential Therapeutic Target for Inflammatory Bowel Disease.

Authors:  Qingqing Du; Yan Qian; Weiwei Xue
Journal:  Front Mol Biosci       Date:  2020-03-04

Review 5.  Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.

Authors:  Kohei Wagatsuma; Yoshihiro Yokoyama; Hiroshi Nakase
Journal:  Life (Basel)       Date:  2021-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.